Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China

ConclusionInsulin glargine is not associated with the risk of overall and site-specific cancers compared to NPH insulin among patients with type 2 diabetes mellitus.
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research